Nirmidas Biotech Raises $2M in seed round for fluorescent dye meant for diagnostics

Stanford University spinout Nirmidas Biotech has raised $2 million in seed funding to commercialize its fluorescence technology that enhances 100-fold a researcher’s ability to detect disease biomarkers, said the company’s R&D director Joshua Robinson. It’s meant to pick up the subtle traces found in blood from early-stage cancer or hard-to-read autoimmune disorders – conditions that typically use fluorescent dye tests."